Overview
Giulio Lupidi practices practicing medicine in Camerino, Italy.
His clinical expertise encompasses Obesity, Malaria, Non-Alcoholic Fatty Liver Disease, and Triple-Negative Breast Cancer.
He is actively involved in clinical research, co-authoring 82 peer reviewed articles.
Gender
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Giulio Lupidi
Is Giulio Lupidi a top-rated expert for Obesity?
MediFind is an objective health platform that identifies experts based on real-world data. Giulio Lupidi is classified as an Experienced expert for Obesity, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Giulio Lupidi participate in research or clinical trials?
Yes. Giulio Lupidi has published 82 articles and abstracts on conditions like Obesity. You can view a list of Giulio Lupidi's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- MalariaMr. Lupidi isExperienced. Learn about Malaria.
- Non-Alcoholic Fatty Liver DiseaseMr. Lupidi isExperienced. Learn about Non-Alcoholic Fatty Liver Disease.
- ObesityMr. Lupidi isExperienced. Learn about Obesity.
- Triple-Negative Breast CancerMr. Lupidi isExperienced. Learn about Triple-Negative Breast Cancer.